Kailera Therapeutics Secures $600 Million in Funding
Kailera Therapeutics, a startup focused on obesity drugs, has raised $600 million in one of the largest private financing rounds of the year for a biotech company.
The financing was led by Bain Capital's private equity group and included investments from Royalty Pharma, the Qatar sovereign wealth fund, and the asset manager of Canada's national pension plan. Several of Kailera's founding investors also participated in the round.
This significant investment highlights the ongoing interest in weight loss drugs, despite some clinical disappointments in recent years. Notably, Kailera's Series B round comes almost exactly one year after the startup launched with $400 million and follows Pfizer's announcement to acquire Metsera, another privately held obesity drug developer, for $4.9 billion.
The deal underlines the persistent heightened attention being paid to weight loss drugs.
- Investors: Bain Capital, Royalty Pharma, Qatar sovereign wealth fund, Canada's national pension plan asset manager
- Funding amount: $600 million
- Series B round announced one year after startup launch with $400 million
Author's summary: Kailera Therapeutics raises $600 million in funding for obesity drugs.